{"result": {"id": "chatcmpl-526", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**APATINIB** is a specific selective VEGFR-2 tyrosine kinase inhibitor being investigated for cancer treatment. It is also an antiangiogenic drug, meaning it inhibits the formation of new blood vessels, and falls under the category of targeted kinase inhibitors (TKIs). \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743185910, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 58, "prompt_tokens": 191, "total_tokens": 249, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"APATINIB\"\nDescription List: [\"A specific selective VEGFR-2 tyrosine kinase inhibitor being investigated for cancer treatment\", \"The **APATINIB** is an antiangiogenic drug, another type of targeted kinase inhibitor (TKI) used in the study. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_4f034d535353edd045b59dc0ecde8c38ad0ec2a92d111e3d4581d479fd5ff32d_v2"}